Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2021 08:15 ET | Source: Cassava Sciences, Inc.

Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference

AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will...
September 03, 2021 07:00 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Releases a Public Statement Regarding Recent Allegations

AUSTIN, Texas, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a public statement regarding recent...
August 27, 2021 11:32 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients

AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau...
August 25, 2021 06:00 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Responds to Allegations

AUSTIN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today issued a response to claims that were posted...
August 24, 2021 08:15 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

AUSTIN, Texas, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the...
August 03, 2021 08:30 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Reports Second Quarter 2021 Financial Results

AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
August 02, 2021 19:54 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending...
July 29, 2021 09:53 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease

Simufilam Significantly Improved Biomarkers in Alzheimer’s Patients Treated for 6 MonthsRobust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p<...
July 29, 2021 09:53 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease

Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 MonthsCognition Improved 3.0 Points on ADAS-Cog at 9 Months (p<0.001) Cognitive...
July 26, 2021 08:30 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam

SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam TreatmentSimufilam 100 mg and 50 mg Reduced Plasma Levels of...